Nanotechnology-based combinational strategies toward the regulation of myofibroblasts and diseased microenvironment in liver fibrosis and hepatic carcinoma  

作　　者：Fenfen Li Ying Zhao Guangjun Nie 

机构地区：[1]School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China [2]CAS Center for Excellence in Nanoscience,National Center for Nanoscience and Technology,Beijing 101408,China [3]Center of Materials Science and Optoelectronics Engineering,University of Chinese Academy of Sciences,Beijing 100049,China [4]GBA National Institute for Nanotechnology Innovation,Guangzhou 510530,China

出　　处：《Nano Research》2023年第12期13042-13055,共14页纳米研究（英文版）

基　　金：sponsored by the National Natural Science Foundation of China(Nos.52173120 and 21877023);the Youth Innovation Promotion Association CAS(No.2021018);the Beijing Natural Science Foundation(No.L222015);the Key Area R&D Program of Guangdong Province(No.2020B0101020004);the Beijing Nova Program(No.20220484233).

摘　　要：Liver fibrosis and hepatic carcinoma(HCC)pose a huge challenge worldwide due to the lack of effective treatment options for end-stage liver diseases.According to their functions and roles,hepatic myofibroblasts mainly include nontumoral fibroblasts(mainly activated hepatic stellate cells(HSCs)),which are involved in the wound-healing process of liver fibrosis,and cancer-associated fibroblasts(CAFs)in hepatic HCC.HSCs play a significant role in regulating extracellular matrix(ECM)deposition in progressive liver fibrosis.CAFs can be derived from activated HSCs and differentiate into ECM-producing myofibroblasts.Moreover,growing evidence shows that CAFs are the primary regulators of the HCC microenvironment,releasing growth factors and cytokines and suppressing the antitumor immune response.Combined therapeutic strategies show reduced drug resistance and side effects.Nanotechnology-based combined strategies aim to improve the delivery efficiency of various therapeutic agents with reduced toxicity via multiple mechanisms.In this review,we will discuss recent developments in combinational strategies based on nanotechnology that regulate myofibroblasts and the diseased microenvironment for liver fibrosis and HCC treatment.We will also identify the major challenges that the field is facing and offer some insights for future drug discovery.

关 键 词：FIBROBLASTS liver fibrosis hepatic carcinoma NANOTECHNOLOGY 

分 类 号：R575[医药卫生—消化系统] TB383[医药卫生—内科学]